Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)
1 other identifier
observational
6
1 country
9
Brief Summary
Mosunetuzumab is a T-cell bispecific antibody targeting CD20 and CD3 aiming to redirect T cells to engage and eliminate malignant B cells. Bispecific antibodies (BsAb) are a promising treatment option which can induce long-term responses in refractory and relapsed B cell lymphoma patients. However, the factors determining the quality and duration of responses are poorly understood.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Nov 2022
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 2, 2022
CompletedFirst Posted
Study publicly available on registry
September 7, 2022
CompletedStudy Start
First participant enrolled
November 7, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 22, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 22, 2024
CompletedJanuary 24, 2025
January 1, 2025
1.2 years
September 2, 2022
January 23, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Capacity of sampling
number of samples collected
2 years
Eligibility Criteria
patients who participate to CELESTIMO study (NCT04712097)
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
- The Lymphoma Academic Research Organisationlead
- Roche Pharma AGcollaborator
Study Sites (9)
Centre Hospitalier de La Cote Basque; Hematologie
Bayonne, 64109, France
Hopital Claude Huriez; Hematologie
Lille, 59037, France
Institut Paoli Calmettes
Marseille, 13273, France
CHU Saint Eloi; Service d'Hématologie Clinique
Montpellier, 34295, France
CHU NANTES - Hôtel Dieu; Service d'Hematologie Clinique
Nantes, 44000, France
CHU de Nîmes - Hôpital Carémeau
Nîmes, 30029, France
Hopital Saint Antoine; Hematologie Clinique
Paris, 75012, France
Hopital De La Miletrie; Hematologie Et Oncologie Medicale
Poitiers, 86021, France
CHU Pontchaillou
Rennes, 35033, France
Biospecimen
* Lymph node biopsies: Cryostor, Formalin-Fixed, Paraffin-Embedded (FFPE), and frozen * Whole blood * Bone marrow aspiration
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Camille Laurent, MD
Oncopole - Toulouse France
- PRINCIPAL INVESTIGATOR
Karin Tarte, PhD
Micro-environnement et cancer (MICA) - Rennes France
- PRINCIPAL INVESTIGATOR
Franck MORSCHHAUSER, MD
Centre Hospitalier Universitaire de Lille - Lille France
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 2, 2022
First Posted
September 7, 2022
Study Start
November 7, 2022
Primary Completion
January 22, 2024
Study Completion
January 22, 2024
Last Updated
January 24, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will not share